SMi Group announces the 10th Annual RNA Therapeutics Conference

20 - 21 February 2019, London, UK.
Undoubtedly, the field of RNA therapeutics is currently undergoing a major expansion, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come.

Fulfilling the potential of genetic discoveries requires the development of therapeutics that can specifically modulate the expression of disease-relevant genes. RNA-based drugs, including siRNAs and antisense nucleotides, are promising examples of a newer class of biologics. Researchers have tried to overcome the major challenges for utilising RNAs in a therapeutic context, including: intracellular delivery, stability and immunogenicity.

Join the 10th Annual RNA Therapeutics Conference in February 2019, for SMi's 10th annual sell out event. Bringing together industry experts from leading RNA companies, to discuss the challenges for clinical translation of RNA-based therapeutics, with an emphasis on recent advances in delivery technologies, and present an overview of the applications of RNA-based drugs for modulation of gene and protein expression, and genome editing.

Network and learn from key opinion leaders such as:

Chairs for 2019

Ekkehard Leberer, Senior Director, Alliance Management, Sanofi

Shalini Andersson, Senior Director and Head of New Modalities, AstraZeneca

Guest Speakers

Carsten Rudolf, Chief Executive Officer, EthrisGmbh

Paul Agris, Founder and Director, The RNA Institute

Keynote Speakers

Marian Gindy, Executive Director, Pharmaceutical Sciences, Merck Research Labs, Merck & Co, inc.

David Giljohan, CEO, Exicure

Ingmar Hoerr, Founder & CEO, CureVac AG

David Blakey, Chief Scientific Officer, MiNA Therapeutics

André Gerber, Professor of RNA Biology, University of Surrey

Heinrich Haas, Vice President Drug Delivery, BioNTech RNA Pharmaceuticals

Markus Mandler, Chief Scientific Officer, Accanis Biotech

Troels Koch, Vice President & Head of Research, RNA Therapeutics, Roche

Hans Kistemaker, Associate Director, ProQR

2019 Featured Highlights

Discover the clinical progress of Spherical Nucleic Acids at Exicure

Understand Sanofi's strategies to deliver therapeutic oligonucleotides across biobarriers

Learn from ProQR how to plan for oligonucleotide supply from personalized medicine to large scale markets

Explore the development of small activating RNA - from bench to bedside with MiNA Therapeutics

Gain insight into the discovery and development of self-amplifying mRNA vaccines at GSK

For further information and to register, please visit:
http://www.therapeutics-rna.com/wpn

Early-Bird Rates

Register by 31st October and save £400

Register by 30th November and save £200

Register by 15th December and save £100